Search
SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreSWG Educational Activities
Recruitment trialsRecruitment is underway for the following trials:
Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.
SWG Educational Activities
EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).
Read morePublications
Original scientific publications
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux…
Selected EMA news
November 2024New medicines recommended for approval
Eltrombopag Viatris (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C (disease in which patients have low levels of blood platelets)
Alhemo (concizumab)
Prevention of bleeding in patients with hemophilia A…
Highlights of Past EHA - Cairo 2017
Dates: September 14 - 15, 2017
Location: Cairo, Egypt
Chairs:
Prof Azza Kamel, Secretary General, Egyptian Society of Hematology and Research (ESHR)
Prof Amal El-Beshlawy, Vice President, Egyptian Society of Hematology and Research (ESHR)
Prof John Gribben, President elect, European Hematology Association (EHA)
Prof Mohamad Qari, President, Pan…
EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies
In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)
Online registration is closed.
Restrictions
EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.
Read more- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- »